The GLP-1 receptor agonist market consists of sales, by entities (organizations, sole traders, or partnerships), of products and services related to GLP-1 receptor agonist, that gained approval for use in individuals with obesity, including those without diabetes, to assist in achieving and maintaining weight loss, especially in cases where traditional lifestyle interventions have been ineffective
doi: 10.1210/jc.2004-0501 96 CordidoFPeinoRPenalvaAAlvarezCVCasanuevaFFDieguezC
In adults over 65 who already have reduced bone mass, any additional decline increases fracture risk
Implications for employers: - This demonstrates that two of the GLP-1 drugs (tirzepatide and semaglutide, both injectable) are associated with much more weight loss than even especially effective diets
GLP-1 Medications and Your Vision: What You Should Know How GLP-1s Can Affect Eye Health Published March 2026 GLP1 medications short for glucagon-like peptide1 receptor agonists (GLP1 RAs) and GLP1 receptor agonists have become a popular option for people managing Type 2 diabetes, lowering blood sugar and helping with weight loss